Covered recipient · General Payments record
MARY DENISE HUGHES
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$13,219.68
129 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,030.00 | 3 |
| Food and Beverage | $3,040.90 | 122 |
| Consulting Fee | $2,475.00 | 1 |
| Travel and Lodging | $1,673.78 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $4,756.34 | 15 |
| EMD Serono, Inc. | $4,647.88 | 20 |
| E.R. Squibb & Sons, L.L.C. | $1,890.00 | 1 |
| TG Therapeutics, Inc. | $352.12 | 8 |
| ABBVIE INC. | $226.43 | 13 |
| Teva Pharmaceuticals USA, Inc. | $222.95 | 29 |
| Hyperfine Operations, Inc. | $116.93 | 1 |
| Novartis Pharmaceuticals Corporation | $116.70 | 5 |
| Alexion Pharmaceuticals, Inc. | $111.00 | 5 |
| ACADIA Pharmaceuticals Inc | $80.46 | 3 |
| Lilly USA, LLC | $75.80 | 4 |
| Vanda Pharmaceuticals Inc. | $74.34 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $72.50 | 3 |
| Tonix Medicines, Inc. | $65.91 | 2 |
| GENZYME CORPORATION | $50.21 | 2 |
| Cycle Pharmaceuticals Inc | $50.14 | 2 |
| Axsome Therapeutics, Inc. | $41.87 | 2 |
| UCB, Inc. | $40.76 | 1 |
| Genentech USA, Inc. | $40.03 | 2 |
| PFIZER INC. | $39.03 | 2 |
| Amneal Pharmaceuticals LLC | $29.22 | 1 |
| Biogen, Inc. | $26.16 | 1 |
| Impel Pharmaceuticals LLC | $24.16 | 1 |
| Neurocrine BioSciences, Inc. | $23.94 | 1 |
| Grifols USA, LLC | $23.91 | 1 |
| Eisai Inc. | $20.89 | 1 |
Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARY DENISE HUGHES
NPI 1275643561 · CMS profile ID 329730
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
GREENVILLE, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275643561?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275643561?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275643561?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1275643561?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
129 matching records · $13,219.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–129 of 129.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $6.10 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247311888 | CMS |
| Amgen Inc. | $16.73 | 02/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399264 | CMS |
| Amgen Inc. | $60.81 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399272 | CMS |
| Cycle Pharmaceuticals Inc | $15.30 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248900999 | CMS |
| ACADIA Pharmaceuticals Inc | $26.91 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247776891 | CMS |
| Novartis Pharmaceuticals Corporation | $24.36 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200208947 | CMS |
| Teva Pharmaceuticals USA, Inc. | $6.34 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247311886 | CMS |
| Amgen Inc. | $327.26 | 01/31/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226891096 | CMS |
| Amgen Inc. | $375.44 | 01/31/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226895265 | CMS |
| Amgen Inc. | $971.08 | 01/31/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226911171 | CMS |
| Amgen Inc. | $94.72 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399266 | CMS |
| Amgen Inc. | $60.89 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399270 | CMS |
| Amgen Inc. | $41.94 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399276 | CMS |
| Amgen Inc. | $124.64 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228399274 | CMS |
| EMD Serono, Inc. | $345.00 | 01/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236868044 | CMS |
| ABBVIE INC. | $24.44 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202078861 | CMS |
| ABBVIE INC. | $8.42 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202078863 | CMS |
| EMD Serono, Inc. | $5.47 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236897658 | CMS |
| Lilly USA, LLC | $13.98 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186810551 | CMS |
| EMD Serono, Inc. | $3,795.00 | 01/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236897974 | CMS |
| TG Therapeutics, Inc. | $24.48 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226267764 | CMS |
| Teva Pharmaceuticals USA, Inc. | $5.88 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247311884 | CMS |
| Neurocrine BioSciences, Inc. | $23.94 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243009829 | CMS |
| EMD Serono, Inc. | $10.94 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1236919753 | CMS |
| ABBVIE INC. | $16.38 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202078859 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,890.00 | 01/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184877815 | CMS |
| TG Therapeutics, Inc. | $33.71 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226267744 | CMS |
| Teva Pharmaceuticals USA, Inc. | $6.22 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247311882 | CMS |
| Alexion Pharmaceuticals, Inc. | $23.11 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202940636 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $124.67 | 2 |
| PY2025 | Principal investigator | $873,707.70 | 120 |
| PY2024 | Recipient | $2,475.64 | 15 |
| PY2024 | Principal investigator | $856,148.84 | 102 |
| PY2023 | Recipient | $2,733.96 | 2 |
| PY2023 | Principal investigator | $989,172.06 | 137 |
| PY2022 | Recipient | $424.00 | 1 |
| PY2022 | Principal investigator | $1,107,607.95 | 91 |
| PY2021 | Recipient | $195.16 | 1 |
| PY2021 | Principal investigator | $779,515.43 | 65 |
| PY2020 | Recipient | $11,016.00 | 1 |
| PY2020 | Principal investigator | $526,767.78 | 30 |
| PY2019 | Principal investigator | $771,057.05 | 69 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
122 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202534679 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $51,500.00 | 12/17/2025 | Non-covered Recipient Entity LIFESTYLE NEUROLOGY, LLC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190308818 |
| Principal investigator 1 | Roche Products Limited | $1,000.00 | 12/10/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617171 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,628.49 | 12/09/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199075 |
| Principal investigator 1 | ABBVIE INC. | $8,227.80 | 12/04/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527788 |
| Principal investigator 1 | EMD Serono, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118403 |
| Principal investigator 1 | EMD Serono, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118406 |
| Principal investigator 1 | ABBVIE INC. | $3,329.20 | 11/05/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522141 |
| Principal investigator 1 | TG Therapeutics, Inc. | $16,495.54 | 11/01/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199073 |
| Principal investigator 1 | ABBVIE INC. | $9,839.34 | 10/30/2025 | Non-covered Recipient Entity INTERSPOND LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202519881 |
| Principal investigator 1 | ABBVIE INC. | $8,863.40 | 10/09/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202515163 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,067.44 | 10/07/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199065 |
| Principal investigator 1 | Amgen Inc. | $21,500.00 | 10/03/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246646739 |
| Principal investigator 1 | TG Therapeutics, Inc. | $23,124.03 | 09/30/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199025 |
| Recipient | Novartis Pharma AG | $76.67 | 09/24/2025 | Covered Recipient Physician | CLOU064C12301, CLOU064C12302 | No dispute reported | 06/30/2026 | 1248109407 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 09/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617157 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 09/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617165 |
| Principal investigator 1 | GENZYME CORPORATION | $61,211.00 | 09/15/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148231 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,333.82 | 09/01/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190305543 |
| Principal investigator 1 | TG Therapeutics, Inc. | $23,215.91 | 08/31/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199023 |
| Principal investigator 1 | GENZYME CORPORATION | $1,860.00 | 08/25/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148227 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 08/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617149 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 08/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617161 |
| Principal investigator 1 | Roche Products Limited | $5.30 | 08/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617169 |
| Principal investigator 1 | EMD Serono, Inc. | $500.00 | 08/01/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118399 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,575.34 | 07/31/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199021 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,736.04 | 07/14/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199059 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,736.04 | 07/07/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199057 |
| Principal investigator 1 | ABBVIE INC. | $9,913.40 | 07/02/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202496485 |
| Principal investigator 1 | Genentech, Inc. | $15,341.00 | 07/01/2025 | Non-covered Recipient Entity INTERSPOND LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211617275 |
| Principal investigator 1 | EMD Serono, Inc. | $561.00 | 06/19/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118392 |
| Principal investigator 1 | EMD Serono, Inc. | $561.00 | 06/19/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118396 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616939 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616946 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616955 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616958 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616962 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616966 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616970 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616985 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616992 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616997 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617009 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617013 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617022 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617025 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617029 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617032 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617047 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617050 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617055 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617059 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617070 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617074 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617079 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617094 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617101 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617105 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617108 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617112 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617125 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617133 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617142 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617145 |
| Principal investigator 1 | ABBVIE INC. | $4,946.20 | 06/03/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202488089 |
| Principal investigator 1 | TG Therapeutics, Inc. | $8,453.00 | 06/01/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198959 |
| Principal investigator 1 | GENZYME CORPORATION | $7,500.00 | 05/19/2025 | Non-covered Recipient Entity Interspond LLC | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148036 |
| Principal investigator 1 | GENZYME CORPORATION | $9,459.00 | 05/19/2025 | Non-covered Recipient Entity Interspond LLC | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148041 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616928 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616932 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616937 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616943 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616951 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616974 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616977 |
| Principal investigator 1 | Roche Products Limited | $439.86 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616981 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211616988 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617000 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617005 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617035 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617039 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617043 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617063 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617067 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617085 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617090 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617097 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617128 |
| Principal investigator 1 | Roche Products Limited | $544.03 | 05/16/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211617137 |
| Principal investigator 1 | ABBVIE INC. | $18,461.80 | 05/07/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202483807 |
| Principal investigator 1 | EMD Serono, Inc. | $500.00 | 05/05/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118388 |
| Principal investigator 1 | Eli Lilly and Company | $2,182.77 | 04/23/2025 | Non-covered Recipient Entity INTERSPOND LLC | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 1187882182 |
| Principal investigator 1 | EMD Serono, Inc. | $300.00 | 04/09/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118105 |
| Principal investigator 1 | EMD Serono, Inc. | $1,280.00 | 04/09/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118109 |
| Principal investigator 1 | EMD Serono, Inc. | $330.00 | 04/09/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118113 |
| Recipient | Eli Lilly and Company | $48.00 | 04/08/2025 | Covered Recipient Physician | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 1187871083 |
| Principal investigator 1 | GENZYME CORPORATION | $5,362.00 | 04/07/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226147888 |
| Principal investigator 1 | ABBVIE INC. | $10,341.80 | 04/03/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202473838 |
| Principal investigator 1 | GENZYME CORPORATION | $4,000.00 | 04/02/2025 | Non-covered Recipient Entity Interspond LLC | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226147867 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,000.00 | 04/01/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198949 |
| Principal investigator 1 | TG Therapeutics, Inc. | $52,340.72 | 04/01/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198957 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,070.34 | 04/01/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199005 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,725.00 | 03/31/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198955 |
| Principal investigator 1 | EMD Serono, Inc. | $770.00 | 03/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118117 |
| Principal investigator 1 | Eli Lilly and Company | $7,400.00 | 03/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 1187883234 |
| Principal investigator 1 | EMD Serono, Inc. | $1,500.00 | 03/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118373 |
| Principal investigator 1 | EMD Serono, Inc. | $2,452.00 | 03/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118377 |
| Principal investigator 1 | EMD Serono, Inc. | $1,000.00 | 03/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118381 |
| Principal investigator 1 | ABBVIE INC. | $4,922.40 | 03/07/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202459596 |
| Principal investigator 1 | PFIZER INC. | $392.22 | 03/06/2025 | Non-covered Recipient Entity Interspond LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767017 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,061.00 | 02/28/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198953 |
| Principal investigator 1 | GENZYME CORPORATION | $1,537.50 | 02/24/2025 | Non-covered Recipient Entity Interspond LLC | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226147856 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,722.44 | 02/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190299619 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,269.76 | 02/17/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226199001 |
| Principal investigator 1 | Eli Lilly and Company | $900.00 | 02/12/2025 | Non-covered Recipient Entity INTERSPOND LLC | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | No dispute reported | 06/30/2026 | 1187882090 |
| Principal investigator 1 | ABBVIE INC. | $11,177.60 | 02/06/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY PC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202449606 |
| Principal investigator 1 | TG Therapeutics, Inc. | $10,870.00 | 01/31/2025 | Non-covered Recipient Entity Premier Neurology | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198951 |
| Principal investigator 1 | EMD Serono, Inc. | $500.00 | 01/28/2025 | Non-covered Recipient Entity INTERSPOND LLC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118385 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,827.00 | 01/28/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190299603 |
| Principal investigator 1 | GENZYME CORPORATION | $11,747.00 | 01/21/2025 | Non-covered Recipient Entity Interspond LLC | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226147978 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,737.68 | 01/09/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190305541 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $245,037.84 | 01/01/2025 | Non-covered Recipient Entity PREMIER NEUROLOGY | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190305545 |